Lead Product(s) : Tiotropium Bromide,Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : STIOLTO RESPIMAT (tiotropium bromide and olodaterol) Inhalation Spray is a prescription medicine used long term, 2 puffs 1 time each day, in controlling symptoms in adults with chronic obstructive pulmonary disease (COPD).
Product Name : Stiolto Respimat
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 17, 2022
Lead Product(s) : Tiotropium Bromide,Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase IV
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olodaterol is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 18, 2020
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase IV
Sponsor : Boehringer Ingelheim GmbH
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Olodaterol is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 20, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
October 09, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of Pulmonary Disease, Chronic Obstructive.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
September 04, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Pulmonary/Respiratory Diseases
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 21, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 20, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability and Pharmacokinetics Study of BI 1744 CL in Healthy Male Subjects
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Study Phase : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BI 1744 CL is a Other Small Molecule drug candidate, which is currently being evaluated in phase I clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 24, 2014
Lead Product(s) : Olodaterol Hydrochloride
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
